Rich and diverse pipeline

Impactful solutions for AMR

BioVersys’ pipeline is focused on addressing the highest unmet medical needs in AMR. We focus on the WHO and CDC highest priority pathogens and the indications with no satisfactory treatment options to date. Our diverse portfolio of innovative, 1st in class and best in class assets is designed to improve patient outcomes.

Lead optimization
Preclinical
Phase 1
Phase 2/3
Partners
BV100 – novel MoA

Serious hospital infections -
A. baumannii

Lead optimization
Preclinical
Phase 1
Phase 2/3
BVL-GSK098 – novel potentiator MoA

MDR-TB

Lead optimization
Preclinical
Phase 1
Phase 2/3
BV200 – novel anti-virulence MoA

(1) Community and hospital infections Staph. aureus
(2) Atopic dermatitis

Lead optimization
Preclinical
Phase 1
Phase 2/3
1
2
BV300 - novel class

ESKAPE pathogens

Lead optimization
Preclinical
Phase 1
Phase 2/3

Finding a diamond. BV100 has a novel mode of action addressing carbapenem resistant Acinetobacter baumannii (CRAB) lung and blood stream infections. CRAB is one of three highest priority pathogens on the WHO and CDC list and responsible for high mortality rates in intensive care units. BioVersys has developed and patented a new formulation of an already approved, safe drug that was previously unknown to be active on CRAB.

Creating a paradigm shift. Transcriptional Regulator Inhibitory Compounds (TRIC) have the potential to create a paradigm shift in treatment options for AMR and targeted microbiome manipulation. BVL-GSK098 reverses the resistance and potentiates the activity of ethionamide (Eto)/prothionamide (Pto) for the treatment of Tuberculosis. BV200 abolishes toxin production of Staphylococcus aureus to improve the outcome of severe hospital infections and reduce inflammation in atopic dermatitis patients.

Introducing a novel class. BV300, a novel chemical class, the Pyrrolocytosines, acts on a new binding site on the bacterial Ribosome, offering a unique opportunity to develop a new broad-spectrum (ESKAPE) antibiotic. No new class of truly broad-spectrum antibiotic has reached the market in more than 4 decades.